Prepare for your visit

Michael R Mcclaid

Family Medicine · Bremen, IN · NPI 1003831207

One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.

What was reported

$4,156.81

in general payments reported to CMS, 2019-2025 · $774 in 2025

The $774 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).

Who reported paying

General payments only, top 6 by amount.

Astrazeneca Pharmaceuticals LP $542.29
Abbvie INC. $511.86
Novo Nordisk INC $348.28
Pfizer INC. $312.15
Lilly USA, LLC $244.93
Bayer Healthcare Pharmaceuticals INC. $225.58

Drugs and devices associated with these payments

Vraylar Nurtec Odt Farxiga Zavzpret Airsupra Jardiance Kerendia Ozempic Rybelsus Caplyta Breztri Comirnaty

Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.

Questions you might ask

I saw Michael Mcclaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?
Is there a generic or alternative to this medication, and would it work as well for me?
What made you choose this particular treatment for my situation?

These are normal questions. A good clinician will welcome them.

Notes

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.

GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/45403/michael-r-mcclaid